Atosiban Interacts with Growth Hormones As Adjuvants in Frozen-thawed Embryo Transfer Cycles

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jun 6

PMID 38841302

Authors

Haixiao Chen

Jiali Cai

Xiaohua Sun

Lanlan Liu

Zhenfang Liu

Peng Gao

Xiaoming Jiang

Jianzhi Ren

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the interaction between atosiban and growth hormone (GH) as adjuvants in frozen-thawed embryo transfer (FET) cycles.

Method: A total of 11627 patients who underwent FET at Xiamen University Affiliated Chenggong Hospital between January 2018 to December 2022 were retrospectively analyzed. Among them, 482 patients received atosiban and 275 patients received GH. The interactions were estimated by comparing the odds ratio (OR) for pregnancy comparing patients with or without atosiban adjuvant in cohorts stratified according to the presence of GH use in either the overall cohort or a propensity score (PS) matched cohort. An interaction term (atosiban × GH) was introduced to a multivariate model to calculate the ratio of OR (ORR) adjusted for confounders.

Results: For all patients receiving atosiban administration, no obvious effect on pregnancy was observed in comparison with either matched or unmatched controls. However, when the patients were stratified according to GH administration, atosiban showed a significant association with clinical pregnancy in comparison with either matched or unmatched controls among patients with GH treatment with rate ratios (RR) of 1.32 (95%CI: 1.05,1.67) and 1.35 (95%CI: 1,1.82), respectively. On the other hand, however, the association was absent among patients without GH treatment. The adjusted ORRs in both matched and unmatched cohorts were 2.44 (95%CI: 1.07,5.84) and 1.95 (95%CI: 1.05, 3.49) respectively.

Conclusion: The combination use of atosiban and GH in FET cycles is potentially beneficial to the pregnancy. However, indications for the use of atosiban and GH may need further assessment.

References

Tang C, Li Q, Chen F, Cai C, Dong Y, Wu Y . A randomized double blind comparison of atosiban in patients with recurrent implantation failure undergoing IVF treatment. Reprod Biol Endocrinol. 2022; 20(1):124. PMC: 9389813. DOI: 10.1186/s12958-022-00999-y. View

Sohlstrom A, Carlsson-Skwirut C, Bang P, Brismar K, Uvnas-Moberg K . Effects of oxytocin treatment early in pregnancy on fetal growth in ad libitum-fed and food-restricted rats. Pediatr Res. 1999; 46(3):339-44. DOI: 10.1203/00006450-199909000-00016. View

Rombauts L, McMaster R, Motteram C, Fernando S . Risk of ectopic pregnancy is linked to endometrial thickness in a retrospective cohort study of 8120 assisted reproduction technology cycles. Hum Reprod. 2015; 30(12):2846-52. DOI: 10.1093/humrep/dev249. View

Altmae S, Mendoza-Tesarik R, Mendoza C, Mendoza N, Cucinelli F, Tesarik J . Effect of Growth Hormone on Uterine Receptivity in Women With Repeated Implantation Failure in an Oocyte Donation Program: A Randomized Controlled Trial. J Endocr Soc. 2018; 2(1):96-105. PMC: 5779111. DOI: 10.1210/js.2017-00359. View

He Y, Wu H, He X, Xing Q, Zhou P, Cao Y . Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study. Fertil Steril. 2016; 106(2):416-22. DOI: 10.1016/j.fertnstert.2016.04.019. View

Yuan C, Song H, Fan L, Su S, Dong B . The Effect of Atosiban on Patients With Difficult Embryo Transfers Undergoing In Vitro Fertilization-Embryo Transfer. Reprod Sci. 2019; 26(12):1613-1617. DOI: 10.1177/1933719119831791. View

. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011; 26(6):1270-83. DOI: 10.1093/humrep/der037. View

Sirotkin A, Nitray J . Growth hormone and prolactin affect oxytocin, vasopressin, progesterone and cyclic nucleotide secretion by bovine granulosa cells in vitro. J Endocrinol. 1994; 143(3):417-22. DOI: 10.1677/joe.0.1430417. View

Austin P . An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46(3):399-424. PMC: 3144483. DOI: 10.1080/00273171.2011.568786. View

10.

Aslan K, Kasapoglu I, Cinar C, Cakir C, Avci B, Uncu G . Low Molecular Weight Heparin-Aspirin-Prednisolone Combination Does Not Increase the Live Birth Rate in Recurrent Implantation Failure: A Retrospective Cohort Study. Reprod Sci. 2023; 30(11):3253-3260. DOI: 10.1007/s43032-023-01233-9. View

11.

Tyler B, Walford H, Tamblyn J, Keay S, Mavrelos D, Yasmin E . Interventions to optimize embryo transfer in women undergoing assisted conception: a comprehensive systematic review and meta-analyses. Hum Reprod Update. 2022; 28(4):480-500. PMC: 9631462. DOI: 10.1093/humupd/dmac009. View

12.

Sirotkin A . Direct action of growth hormone on bovine ovarian cells: effects on estradiol, oxytocin, vasopressin release by granulosa cells and on oocyte maturation and cleavage in vitro. Ann Endocrinol (Paris). 1996; 57(3):219-24. View

13.

Margalioth E, Ben-Chetrit A, Gal M, Eldar-Geva T . Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod. 2006; 21(12):3036-43. DOI: 10.1093/humrep/del305. View

14.

Gardner D, Vella P, Lane M, Wagley L, Schlenker T, Schoolcraft W . Culture and transfer of human blastocysts increases implantation rates and reduces the need for multiple embryo transfers. Fertil Steril. 1998; 69(1):84-8. DOI: 10.1016/s0015-0282(97)00438-x. View

15.

Cai J, Liu L, Zhang J, Qiu H, Jiang X, Li P . Low body mass index compromises live birth rate in fresh transfer in vitro fertilization cycles: a retrospective study in a Chinese population. Fertil Steril. 2016; 107(2):422-429.e2. DOI: 10.1016/j.fertnstert.2016.10.029. View

16.

Xue-Mei W, Hong J, Wen-Xiang Z, Yang L . The effects of growth hormone on clinical outcomes after frozen-thawed embryo transfer. Int J Gynaecol Obstet. 2016; 133(3):347-50. DOI: 10.1016/j.ijgo.2015.10.020. View

17.

Cui N, Li A, Luo Z, Zhao Z, Xu Y, Zhang J . Effects of growth hormone on pregnancy rates of patients with thin endometrium. J Endocrinol Invest. 2018; 42(1):27-35. DOI: 10.1007/s40618-018-0877-1. View

18.

Lensen S, Hammarberg K, Polyakov A, Wilkinson J, Whyte S, Peate M . How common is add-on use and how do patients decide whether to use them? A national survey of IVF patients. Hum Reprod. 2021; 36(7):1854-1861. DOI: 10.1093/humrep/deab098. View

19.

Li X, Du Y, Han X, Wang H, Sheng Y, Lian F . Efficacy of atosiban for repeated implantation failure in frozen embryo transfer cycles. Sci Rep. 2023; 13(1):9277. PMC: 10247710. DOI: 10.1038/s41598-023-36286-y. View

20.

Borroto-Escuela D, Cuesta-Marti C, Lopez-Salas A, Chruscicka-Smaga B, Crespo-Ramirez M, Tesoro-Cruz E . The oxytocin receptor represents a key hub in the GPCR heteroreceptor network: potential relevance for brain and behavior. Front Mol Neurosci. 2023; 15:1055344. PMC: 9812438. DOI: 10.3389/fnmol.2022.1055344. View